Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments

US7524822B2 · kind B2 · utility

Assignees

• Boehringer Ingelheim International GmbH · DE
• Ajinomoto Co., Inc.

Inventors

• Gerd Kraemer · Eberhardzell, DE
• Hans-Juergen Martin · Biberach an der Riß, DE
• Gebhard Adelgoss · Biberach, DE
• Klaus Dugi · Dresden, DE
• Adil Duran · Biberach an der Riß, DE
• Peter Eickelmann · Mittelbiberach, DE
• Steffen Maier · Wettingen, CH
• Sabine Pinnetti · Biberach, DE
• Regine Ritter · Wiesbaden, DE
• Gebhard Schilcher · Mittelbiberach, DE
• Ruediger Streicher · Biberach, DE
• Leo Thomas · Biberach, DE

Key dates

• Filing date: Jan 10, 2007
• Grant date: Apr 28, 2009
• Expiry date: Jan 10, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.